Axial Spondyloarthritis Drugs Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : December 2019 Pages : 180 Category: Pharma & Healthcare Report Code : HC127715
Axial Spondyloarthritis Drugs Market by Type (Etanercept Biosimilar, Secukinumab, Ixekizumab, Certolizumab Pegol) Application (Home Care, Hospital, Clinic) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Axial Spondyloarthritis Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Axial spondyloarthritis is a constant provocative rheumatic issue, which basically influences the hub skeleton. AxSpA is a sort of joint pain that is frequently connected with psoriatic arthritis, reactive arthritis and inflammatory bowel disease. Pivotal spondyloarthritis is isolated into two phases: non-radiographic hub spondyloarthritis and radiographic hub spondyloarthritis. Hereditary qualities assume a significant job as the condition is inheritable, with changes in specific qualities, including the human leukocyte antigen B27 quality, known to be related with an expanded danger of creating pivotal spondyloarthritis. This issue can be determined at a beginning time to have X-beam, though compliance is finished with the assistance of erythrocyte sedimentation rate, attractive reverberation imaging, and C-receptive protein tests.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Novartis AG
- Johnson & Johnson
- Panacea Biotec Ltd
- Eli Lilly and Company
- Sandoz International GmbH
- UCB SA
- Sun Pharma Advanced Research Company Ltd
- AstraZeneca Plc
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Axial Spondyloarthritis Drugs Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Etanercept Biosimilar
o Secukinumab
o Ixekizumab
o Certolizumab Pegol
· Axial Spondyloarthritis Drugs Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Home Care
o Hospital
o Clinic
· Axial Spondyloarthritis Drugs Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Novartis AG
o Johnson & Johnson
o Panacea Biotec Ltd
o Eli Lilly and Company
o Sandoz International GmbH
o UCB SA
o Sun Pharma Advanced Research Company Ltd
o AstraZeneca Plc
· Axial Spondyloarthritis Drugs Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Axial Spondyloarthritis Drugs Market , By Country
o U.S. Axial Spondyloarthritis Drugs Market
o Canada Axial Spondyloarthritis Drugs Market
o Mexico Axial Spondyloarthritis Drugs Market
o Europe
§ Europe Axial Spondyloarthritis Drugs Market , By Country
o Germany Axial Spondyloarthritis Drugs Market
o UK Axial Spondyloarthritis Drugs Market
o France Axial Spondyloarthritis Drugs Market
o Russia Axial Spondyloarthritis Drugs Market
o Italy Axial Spondyloarthritis Drugs Market
o Rest of Europe Axial Spondyloarthritis Drugs Market
o Asia-Pacific
§ Asia-Pacific Axial Spondyloarthritis Drugs Market , By Country
o China Axial Spondyloarthritis Drugs Market
o Japan Axial Spondyloarthritis Drugs Market
o South Korea Axial Spondyloarthritis Drugs Market
o India Axial Spondyloarthritis Drugs Market
o Southeast Asia Axial Spondyloarthritis Drugs Market
o Rest of Asia-Pacific Axial Spondyloarthritis Drugs Market
o South America
§ South America Axial Spondyloarthritis Drugs Market
o Brazil Axial Spondyloarthritis Drugs Market
o Argentina Axial Spondyloarthritis Drugs Market
o Columbia Axial Spondyloarthritis Drugs Market
o Rest of South America Axial Spondyloarthritis Drugs Market
o Middle East and Africa
§ Middle East and Africa Axial Spondyloarthritis Drugs Market
o Saudi Arabia Axial Spondyloarthritis Drugs Market
o UAE Axial Spondyloarthritis Drugs Market
o Egypt Axial Spondyloarthritis Drugs Market
o Nigeria Axial Spondyloarthritis Drugs Market
o South Africa Axial Spondyloarthritis Drugs Market
o Rest of MEA Axial Spondyloarthritis Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Axial Spondyloarthritis Drugs Market, By Type
5.1. Introduction
5.2. Global Axial Spondyloarthritis Drugs Revenue and Market Share by Type (2017-2027)
5.2.1. Global Axial Spondyloarthritis Drugs Revenue and Revenue Share by Type (2017-2027)
5.3. Etanercept Biosimilar
5.3.1. Global Etanercept Biosimilar Revenue and Growth Rate (2017-2027)
5.4. Secukinumab
5.4.1. Global Secukinumab Revenue and Growth Rate (2017-2027)
5.5. Ixekizumab
5.5.1. Global Ixekizumab Revenue and Growth Rate (2017-2027)
5.6. Certolizumab Pegol
5.6.1. Global Certolizumab Pegol Revenue and Growth Rate (2017-2027)
6. Axial Spondyloarthritis Drugs Market, By Application
6.1. Introduction
6.2. Global Axial Spondyloarthritis Drugs Revenue and Market Share by Application (2017-2027)
6.2.1. Global Axial Spondyloarthritis Drugs Revenue and Revenue Share by Application (2017-2027)
6.3. Home Care
6.3.1. Global Home Care Revenue and Growth Rate (2017-2027)
6.4. Hospital
6.4.1. Global Hospital Revenue and Growth Rate (2017-2027)
6.5. Clinic
6.5.1. Global Clinic Revenue and Growth Rate (2017-2027)
7. Axial Spondyloarthritis Drugs Market, By Region
7.1. Introduction
7.2. Global Axial Spondyloarthritis Drugs Revenue and Market Share by Regions
7.2.1. Global Axial Spondyloarthritis Drugs Revenue by Regions (2017-2027)
7.3. North America Axial Spondyloarthritis Drugs by Countries
7.3.1. North America Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Axial Spondyloarthritis Drugs by Countries
7.4.1. Europe Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Axial Spondyloarthritis Drugs by Countries
7.5.1. Asia-Pacific Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Axial Spondyloarthritis Drugs by Countries
7.6.1. South America Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Axial Spondyloarthritis Drugs by Countries
7.7.1. Middle East and Africa Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Novartis AG
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Johnson & Johnson
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Panacea Biotec Ltd
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Eli Lilly and Company
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Sandoz International GmbH
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. UCB SA
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Sun Pharma Advanced Research Company Ltd
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. AstraZeneca Plc
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
9. Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.1. Global Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Axial Spondyloarthritis Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.1.1. United States Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2. Europe Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.2. France Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.3. UK Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.1. China Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.4. India Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.4. South America Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Axial Spondyloarthritis Drugs Market Forecast (2017-2027)
9.3. Axial Spondyloarthritis Drugs Market Forecast by Type (2017-2027)
9.3.1. Axial Spondyloarthritis Drugs Forecast by Type (2017-2027)
9.3.2. Axial Spondyloarthritis Drugs Market Share Forecast by Type (2017-2027)
9.4. Axial Spondyloarthritis Drugs Market Forecast by Application (2017-2027)
9.4.1. Axial Spondyloarthritis Drugs Forecast by Application (2017-2027)
9.4.2. Axial Spondyloarthritis Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Axial Spondyloarthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Axial Spondyloarthritis Drugs Revenue and Revenue Share by Type (2017-2018)
Figure Global Etanercept Biosimilar Revenue and Growth Rate (2017-2018)
Figure Global Secukinumab Revenue and Growth Rate (2017-2018)
Figure Global Ixekizumab Revenue and Growth Rate (2017-2018)
Figure Global Certolizumab Pegol Revenue and Growth Rate (2017-2018)
Table Global Axial Spondyloarthritis Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Home Care Revenue and Growth Rate (2017-2018)
Figure Global Hospital Revenue and Growth Rate (2017-2018)
Figure Global Clinic Revenue and Growth Rate (2017-2018)
Table Global Axial Spondyloarthritis Drugs Revenue by Regions (2017-2018)
Figure North America Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure North America Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2018)
Figure North America Axial Spondyloarthritis Drugs by Countries (2017-2018)
Figure North America Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure United States Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Canada Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Mexico Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Europe Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Axial Spondyloarthritis Drugs by Countries (2017-2018)
Figure Europe Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Germany Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure France Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure UK Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Russia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Italy Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Rest of Europe Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Axial Spondyloarthritis Drugs by Countries (2017-2018)
Figure Asia-Pacific Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure China Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Japan Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Korea Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure India Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Southeast Asia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure South America Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2018)
Figure South America Axial Spondyloarthritis Drugs by Countries (2017-2018)
Figure South America Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Brazil Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Argentina Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Columbia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Rest of South America Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Axial Spondyloarthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Axial Spondyloarthritis Drugs by Countries (2017-2018)
Figure Middle East and Africa Axial Spondyloarthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Egypt Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Nigeria Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure South Africa Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Turkey Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Axial Spondyloarthritis Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Novartis AG Axial Spondyloarthritis Drugs Financial Overview
Table Johnson & Johnson Axial Spondyloarthritis Drugs Financial Overview
Table Panacea Biotec Ltd Axial Spondyloarthritis Drugs Financial Overview
Table Eli Lilly and Company Axial Spondyloarthritis Drugs Financial Overview
Table Sandoz International GmbH Axial Spondyloarthritis Drugs Financial Overview
Table UCB SA Axial Spondyloarthritis Drugs Financial Overview
Table Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Financial Overview
Table AstraZeneca Plc Axial Spondyloarthritis Drugs Financial Overview
Figure Global Axial Spondyloarthritis Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Axial Spondyloarthritis Drugs Market Forecast by Regions (2018-2025)
Figure North America Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure United States Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Canada Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Mexico Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Europe Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Germany Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure France Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure UK Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Russia Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Italy Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Rest of Europe Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure China Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Japan Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Korea Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure India Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Southeast Asia Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure South America Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Brazil Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Argentina Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Columbia Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Rest of South America Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Egypt Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Nigeria Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure South Africa Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Turkey Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Axial Spondyloarthritis Drugs Market Forecast (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Forecast by Type (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Market Share Forecast by Type (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Forecast by Type (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Forecast by Application (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Market Share Forecast by Application (2018-2025)
Figure Global Axial Spondyloarthritis Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|